Gene: EVA1A
Official Full Name: eva-1 homolog A, regulator of programmed cell deathprovided by HGNC
Gene Summary: Predicted to act upstream of or within several processes, including TOR signaling; cardiac left ventricle morphogenesis; and connective tissue replacement. Located in intracellular membrane-bounded organelle and plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00272 | EVA1A Knockout cell line (HeLa) | Human | EVA1A | 1:3~1:6 | Negative | Online Inquiry |
KO25152 | EVA1A Knockout cell line (HCT 116) | Human | EVA1A | 1:2~1:4 | Negative | Online Inquiry |
KO25153 | EVA1A Knockout cell line (HEK293) | Human | EVA1A | 1:3~1:6 | Negative | Online Inquiry |
KO25154 | EVA1A Knockout cell line (A549) | Human | EVA1A | 1:3~1:4 | Negative | Online Inquiry |
EVA1A Gene Knockout Cell Lines are genetically engineered cellular models characterized by the targeted deletion of the EVA1A gene, which encodes the EVA1A protein known for its role in modulating cellular processes related to apoptosis and mitochondrial function. The knockout of EVA1A disrupts these pathways, providing researchers with a powerful tool to explore the gene's biological roles and its implications in various diseases, particularly those associated with impaired cell death or mitochondrial dysfunction.
The key function of these cell lines lies in their ability to serve as a controlled environment for studying the downstream effects of EVA1A deletion. Researchers can examine changes in cell viability, proliferation, and metabolic activity, enabling a detailed assessment of how EVA1A impacts cell fate decisions. Mechanistically, by manipulating various signaling pathways and observing resultant phenotypic changes, scientists can elucidate the function of EVA1A in health and disease.
In terms of scientific importance, EVA1A Gene Knockout Cell Lines are invaluable in basic and translational research settings. Their application spans cancer biology, neurodegenerative diseases, and metabolic disorders, offering insights that could lead to novel therapeutic targets and strategies. The ability to model conditions that mimic human disease states makes these cell lines particularly relevant in preclinical studies.
Compared to traditional cell lines or methods that may have off-target effects, EVA1A Gene Knockout Cell Lines provide a specific and robust system for genetic manipulation studies, minimizing confounding variables. This specificity enhances the reliability of experimental results, making it easier for researchers to draw meaningful conclusions about gene function and its implications.
For researchers and clinicians, the EVA1A Gene Knockout Cell Lines offer a unique resource that can accelerate the understanding of complex biological systems and contribute to the development of precise, targeted interventions. They are especially beneficial for labs focusing on gene therapy or personalized medicine approaches.
At our company, we take pride in our dedication to advancing research tools that empower scientists in their quest for knowledge. Our expertise in genetic engineering and commitment to quality ensure that the EVA1A Gene Knockout Cell Lines are reliable, comprehensively validated, and ready to contribute to groundbreaking discoveries in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.